ADMA BIOLOGICS, INC. Current Liabilities
ADMA BIOLOGICS, INC. (ADMA) had Current Liabilities of $75.76 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Liabilities, Current $75.76M.
- 2026-03-31: Liabilities, Current $73.54M.
- 2025-12-31: Liabilities, Current $69.54M.
- 2025-09-30: Liabilities, Current $56.49M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $75.76M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $73.54M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $69.54M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $56.49M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $74.94M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $53.50M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $55.54M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $44.89M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $44.18M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $53.09M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $49.81M 10-K · filed 2025-03-18 | |
| 2023-09-30 | $41.84M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $41.95M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $36.73M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $39.27M 10-K · filed 2024-02-28 | $39.27M 10-K · filed 2023-03-23 |
| 2022-09-30 | $44.44M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $28.07M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $31.57M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $30.38M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $32.34M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $18.19M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $21.21M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $19.95M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $16.47M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $12.88M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $13.91M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $14.03M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $15.15M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $10.13M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $8.34M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $9.63M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $9.89M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $6.92M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | $9.44M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $9.44M 10-K · filed 2019-03-13 | |
| 2017-09-30 | $13.34M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $15.65M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $12.96M 10-Q · filed 2017-05-12 | |
| 2016-12-31 | $11.22M 10-K · filed 2018-03-29 | |
| 2016-09-30 | $9.21M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $5.08M 10-Q · filed 2016-08-12 | |
| 2016-03-31 | $4.29M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $4.22M 10-K · filed 2017-02-24 | |
| 2015-09-30 | $4.30M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $3.20M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $3.79M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $4.20M 10-K · filed 2016-03-23 | |
| 2014-09-30 | $4.12M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $3.80M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $4.30M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $3.66M 10-K · filed 2015-03-09 | |
| 2013-09-30 | $2.52M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $2.03M 10-Q · filed 2013-08-12 | |
| 2013-03-31 | $2.10M 10-Q · filed 2013-05-14 | |
| 2012-12-31 | $1.82M 10-K · filed 2014-03-28 | |
| 2012-09-30 | $1.40M 10-Q · filed 2012-11-13 | |
| 2012-06-30 | $1.01M 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $1.03M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $2.30M 10-K · filed 2013-03-06 | $5.31K 10-Q · filed 2012-02-01 |
| 2011-09-30 | $9.81K 10-Q · filed 2011-10-28 | |
| 2011-06-30 | $9.82K 10-Q · filed 2012-02-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |